BioVaxys Technology Corp.

BioVaxys is a clinical-stage biopharmaceutical company focused on out-licensing immunotherapy assets developed from its proprietary DPX? platform. The DPX platform has demonstrated safety, tolerability, and efficacy in multiple Phase 1 and Phase 2B clinical studies across oncology, infectious disease, allergy, and autoimmune disorders.

Recent News

Lions Bay Announces Return of Hy and Jay Property

Vancouver, British Columbia--(Newsfile Corp. - April 2, 2019) - Lions Bay Mining Corp. (CSE: LBM) ("Lions Bay" or the "Company") announces that it has terminated the property purchase agreement entered into with Golden Predator Mining Corp. ("Golden Predator") for the sale of certain of its mineral claims located in the Yukon Territory. Under the terms of the property purchase agreement, Golden Predator was required to make cash payments and issue Golden Predator common shares to Lions Bay...

2019-04-02 8:00 AM EDT

Lions Bay Announces Listing on CSE and Completion of Private Placement

Vancouver, British Columbia--(Newsfile Corp. - November 22, 2018) - Lions Bay Mining Corp. (CSE: LBM) ("Lions Bay" or the "Company") is pleased to announce that, effective at the open of market today, its common shares commenced trading on the Canadian Securities Exchange (the "CSE") under the symbol LBM. In addition, the Company announces it has closed a non-brokered private placement (the "Private Placement") offering of 5,000,000 units ("Units") at a price of $0.10 per Unit for gross...

2018-11-22 11:00 AM EST

Ready to Announce with Confidence?

Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us